ArticleFrontiers in medicine2025
The economic ramifications of liver cancer on a global, regional, and national scale.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: A comprehension of the macroeconomic losses on a worldwide, regional, and national scale attributable to liver cancer is crucial for the optimal distribution of medical and research materials. The authors conducted an investigation into the macroeconomic impacts of the strain imposed by liver cancer in 2021 across 185 nations. Methods: The data pertaining to disability-adjusted life years (DALY) for liver cancer and its associated risk factors were sourced from the 2021 records of the Global Burden of Disease investigation. Information pertaining to GDP, modified for purchasing power parity (PPP), originated from the World Bank; the integration of GDP and DALY data facilitated the estimation of macroeconomic losses through the application of a value of lost welfare (VLW) methodology. Every finding is articulated in 2021 international US dollars, calibrated for PPP. Outcomes: In the year 2021, the VLW resulting from liver cancer worldwide amounted to $141.95 B, representing 0.15% of the worldwide GDP. The worldwide VLW/GDP ratio for alcohol-related liver cancer was 0.033% (VLW = $31.835 B) Hepatitis B-associated liver cancer prevalence was 0.041% (VLW = $38.667 B) Hepatitis C-associated liver cancer prevalence was 0.056% (VLW = $53.268 B) incidence of NASH-related liver cancer was 0.012% (VLW = $11.653 B) the incidence of liver cancer attributed to alternative factors was recorded at 0.007% (VLW = $6.728 B). The East Asia, Southeast Asia, and Oceania super-region recorded the greatest VLW/GDP for liver cancer overall was 0.19%, with VLW of $39.08 B, the high-income super-region accounted for the second (VLW/GDP = 0.16%; VLW = $88.00 B). Conclusion: The global macroeconomic burden attributable to liver cancer is substantial, with far-reaching implications for productivity losses and healthcare expenditure. These evidence-based economic estimates provide a compelling rationale for strategic resource allocation towards liver cancer control programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.